1. Home
  2. PNTG vs NTLA Comparison

PNTG vs NTLA Comparison

Compare PNTG & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Pennant Group Inc.

PNTG

The Pennant Group Inc.

HOLD

Current Price

$29.23

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$9.59

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNTG
NTLA
Founded
2019
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
986.9M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
PNTG
NTLA
Price
$29.23
$9.59
Analyst Decision
Strong Buy
Buy
Analyst Count
7
22
Target Price
$35.33
$19.83
AVG Volume (30 Days)
249.5K
3.6M
Earning Date
11-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
10.47
N/A
EPS
0.75
N/A
Revenue
$847,274,000.00
$57,528,000.00
Revenue This Year
$36.69
$1.96
Revenue Next Year
$24.06
N/A
P/E Ratio
$38.88
N/A
Revenue Growth
29.89
33.52
52 Week Low
$21.18
$5.90
52 Week High
$30.46
$28.25

Technical Indicators

Market Signals
Indicator
PNTG
NTLA
Relative Strength Index (RSI) 61.73 47.26
Support Level $28.99 $8.74
Resistance Level $29.91 $9.85
Average True Range (ATR) 0.68 0.47
MACD -0.14 0.30
Stochastic Oscillator 38.19 70.25

Price Performance

Historical Comparison
PNTG
NTLA

About PNTG The Pennant Group Inc.

Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: